LONDON, March 28, 2017 /PRNewswire/ -- The global emerging cancer diagnostics market is expected to grow at a CAGR of 13.45% from 2016 to 2023 and reach a figure of $6.34 billion by 2023.
Description Cancer is a chronic disease and is affecting a huge population. Many technologies are emerging in the cancer diagnostics market. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor
test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others. This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report. All of the above mentioned report coverage parameters are discussed across different regions such as North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW). While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market. The answers to the following key questions can be found in the report: - What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases? - How is the tumor biomarker test market evolving? - What are the market shares of the leading segments of the tumor biomarker test market in 2015? - How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023? - How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023? - How the industry will evolve during the forecast period between 2017 and 2023? - What are the key developmental strategies implemented in different applications across all regions? - How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others? - Which geographical region will lead the global tumor biomarker test market by the end of the forecast period? - Who are the key players in the tumor biomarker test market? - What are different application in this market and how are they categorized? - What are the market trends and key developments in different geographical regions? - What are all market available cancer biomarker test? - What is the current market size and future projection for emerging cancer technologies in the major countries? - What are the key sources of information about emerging cancer technologies? - What is the incidence rate of major cancer type? The research study tries to answer various aspects of the emerging cancer diagnostics market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter's Five Force model and opportunity matrix for an in-depth study of the emerging cancer diagnostics market and an assessment of the factors governing the same. Executive Summary Cancer is one of the most modernized trends in the healthcare industry. It has shown substantial progress in the last few years being the most commonly found chronic disease which affects, more or less, people of all age groups. The growth of the cancer diagnostics market is attributed majorly to the rapid increase in the oncology population, integration of smart devices with medical devices and advancement of healthcare technologies. The gradual advancement and innovation of new cancer care technologies are contributing to developing a concrete platform for further growth of cancer diagnostics market. With the emergence of advanced technologies such as precision medicine, biomarkers, companion diagnostics, and liquid biopsy into the field of cancer diagnostics, there has been a gradual rise in the overall demand of the newly developed products. Presently, the main focus of government initiatives is mainly towards developing effective solutions, controlling the level of increase in cancer-stricken population, and integrating advanced technologies to fulfil the unmet needs of the patients. In 2015, it was found that approximately 15 million people of the world's population is suffering from this disease and is estimated to reach the double number of patients by the end of 2030. The following figure shows the relation between the total population and cancer population worldwide. There are high chances that the ageing population currently suffering from cancer is also prone to higher risks of complications from this disease such as heart attacks, weak immune systems, kidney failure, amputation and blindness among others. All these issues can be resolved through effective cancer care solutions by providing education and support to patients with chronic conditions. The demand for cancer diagnostics tests are increasing every year due to its easy availability and effectiveness. The global emerging cancer diagnostics market has been identified as one of the fastest growing industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among a plethora of public companies. There is a high prevalence of cancer in low and middle-income countries. This prevalence can be effectively controlled by following simple life measures such as indulging in physical activities, avoiding junk food, avoiding direct sunlight contact, and retaining normal body weight, among others. Governmental regulations and standards play a major role in sustaining the growth and development of the market. The main aim of these regulations is to make diagnostics tests more adaptable and focused towards different types of cancer and also provide modern technologies to the needed people. The patients benefit indirectly through these regulations as it helps them save time and cuts-down the overall cost as the patients receive the required treatment for the disease. The global emerging cancer diagnostics market is expected to grow at a CAGR of 13.45% from 2017 to 2023 and reach a figure of $6.34 billion by 2023. The advancements in technology, adoption of biomarker tests, and increasing cancer incidence rate are some of the major driving factors for this market. The global emerging cancer diagnostics market has been classified on the basis of test type, application and geography. On the basis of the test type, the emerging cancer diagnostics can be segmented in different parts. Among which HER2Test is dominating followed by PSA Tests. There are different types of biomarkers which are used in diagnosis to know the responsible gene for specific cancer type. However, CA Tests, ALK Tests and BRCA Tests are also growing at high rate. There are many types of cancer, but in this report top 20 cancer type has been mentioned. Out of this five cancer types are dominating for which these tests are being used. These are Lung, breast, Colorectal, Prostate and Blood Cancer. However, Stomach, Oesophagus, Ovarian and Cervical Cancer are showing high incidence rate in future. Patents and approvals are essential tools for the companies operating in this market as it helps in gaining the confidence and trust of patient. As the industry evolves, the role of consortiums and regulatory bodies becomes pivotal in shaping the future trajectory. These regulations and compliances help in the increasing adoption of tests and their applications among patient. In this report many recent key developments and market trends have been mentioned. The market is currently driven by partnership and collaborations strategy, in addition to this product launches and government approvals are also playing important role. A huge list of key players are given in the report. Some of the key players are Roche, Thermo Fisher, Agilent, Quest Diagnostics, and Illumina Inc. among others. Download the full report: https://www.reportbuyer.com/product/4800624/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-emerging-cancer-diagnostics-tumor-biomarker-test-market-analysis--forecast-2017-2023-focus-on-biomarker-test-type-application--market-trends-300430636.html